Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a BuyBy legume / March 24, 2024 / Eli Lilly Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy and maintains $850 price target.